Can AngioDynamics (ANGO) Stock Reach $20?

Key Takeaways

• The central $20 price target is the arithmetic mean of four verified analyst targets, which span a wide range from $17 to $24.
• At a recent close near $14.19, reaching $20 would require a gain of roughly 41%, a substantial move.
• Bullish analysts point to NanoKnife adoption in prostate ablation, a newly effective CPT reimbursement code, and above-expectations guidance.
• The company remains unprofitable on a GAAP (Generally Accepted Accounting Principles) basis, with negative EPS (earnings per share), which is a key source of risk.
• Reaching the target likely hinges on sustained NanoKnife procedural growth, reimbursement decisions, and progress toward profitability.

Analyst Price Targets and Consensus View

AngioDynamics, Inc. (ANGO) is a Latham, New York-based medical device maker focused on vascular access, oncology, and thrombus management. Four current analyst price targets were reviewed, ranging from $17 to $24, with an average of $20. That figure is used as the central target here.

The views differ meaningfully. Canaccord Genuity raised its target to $20 from $16 in August 2026, citing a strong close to fiscal 2026 and guidance ahead of expectations, driven by the NanoKnife business. H.C. Wainwright's Yi Chen lifted its target to $19 from $16, highlighting building NanoKnife reimbursement. Lake Street's Frank Takkinen holds the highest target at $24, while Freedom Broker carries a more cautious $17. The spread reflects genuine disagreement about how quickly NanoKnife adoption and profitability will scale.

Current Market Position and Path Toward the Target

Shares recently closed near $14.19, within a 52-week range of roughly $9.39 to $16.29. A move to $20 implies about 41% upside, a substantial appreciation that would require not just a return to prior highs but a decisive breakout above them.

AngioDynamics operates through Med Tech (including Auryon, the thrombus management platform, and NanoKnife) and Med Device segments. NanoKnife, an irreversible electroporation system cleared for prostate tissue ablation, is the central growth story. A CPT Category I reimbursement code took effect in January 2026, a catalyst analysts cite as supporting procedure volume and revenue growth.

What Could Support a Move Toward the Target

• NanoKnife momentum: Fiscal Q4 revenue rose about 8% year over year to roughly $86.6 million, and NanoKnife growth has been a primary driver.
• Reimbursement tailwind: The CPT Category I code for prostate ablation, effective January 2026, removes a key reimbursement barrier, with a pancreatic cancer code expected in January 2027.
• Raised guidance: Management increased fiscal 2026 adjusted EPS and sales outlooks ahead of expectations, supporting recent target increases.
• Clean balance sheet: The company carries minimal debt and substantial cash, providing flexibility to fund growth.

What Could Prevent the Target From Being Reached

• Persistent losses: The company reports negative GAAP EPS, and valuation remains a concern until profitability improves.
• Reimbursement dependency: NanoKnife adoption partly depends on decisions by Medicare Administrative Contractors (MACs), which could lag expectations.
• Slowing legacy businesses: Some segments, such as parts of the thrombus management franchise, have shown year-over-year declines.
• Execution risk: A leadership transition is expected during the first half of fiscal 2027, adding uncertainty to the turnaround.
• Valuation and sentiment: As a small-cap with negative earnings, the stock can compress quickly if growth disappoints.

Technical Levels and Market Structure

The stock trades near the upper end of its 52-week range, with resistance around the $16 to $16.29 zone at the prior high. A sustained move toward $20 would require clearing that resistance. On the downside, support appears near the long-term moving average in the $12 to $13 area, with the 52-week low near $9.39 as a deeper floor. The long-term trend improved over the past year, but the path to $20 depends on maintaining that uptrend.

Time Horizon and What Investors Should Monitor

Analyst targets typically reflect a roughly 12-month horizon, though individual assumptions vary. Investors should watch NanoKnife procedure volumes and probe sales, MAC reimbursement determinations, the planned CEO transition, and any updates to adjusted EPS and revenue guidance. Quarterly earnings, particularly commentary on prostate and pancreatic ablation adoption, are the most direct catalysts for the target.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors following a turnaround story like AngioDynamics, signal-based tools can help track momentum shifts and identify when sentiment is changing.

Final Assessment

The $20 central target reflects the average of four analyst targets spanning $17 to $24, implying a substantial move of roughly 41% from recent levels. The strongest support comes from NanoKnife growth and a new reimbursement code, while the principal obstacles are persistent losses, reimbursement uncertainty, and execution risk around a leadership transition. Analyst disagreement is real, with targets divided between conservative and aggressive adoption scenarios. Whether the shares can reach $20 depends on sustained procedural growth and progress toward profitability, which upcoming earnings and reimbursement decisions will help clarify.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations